Cargando…

A longitudinal study on quality of life along the spectrum of Alzheimer’s disease

BACKGROUND: Quality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time. We aimed to compare the trajectories of QoL between amyloid-positive and amylo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mank, Arenda, Rijnhart, Judith J. M., van Maurik, Ingrid S., Jönsson, Linus, Handels, Ron, Bakker, Els D., Teunissen, Charlotte E., van Berckel, Bart N. M., van Harten, Argonde C., Berkhof, Johannes, van der Flier, Wiesje M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476356/
https://www.ncbi.nlm.nih.gov/pubmed/36109800
http://dx.doi.org/10.1186/s13195-022-01075-8
_version_ 1784790118089883648
author Mank, Arenda
Rijnhart, Judith J. M.
van Maurik, Ingrid S.
Jönsson, Linus
Handels, Ron
Bakker, Els D.
Teunissen, Charlotte E.
van Berckel, Bart N. M.
van Harten, Argonde C.
Berkhof, Johannes
van der Flier, Wiesje M.
author_facet Mank, Arenda
Rijnhart, Judith J. M.
van Maurik, Ingrid S.
Jönsson, Linus
Handels, Ron
Bakker, Els D.
Teunissen, Charlotte E.
van Berckel, Bart N. M.
van Harten, Argonde C.
Berkhof, Johannes
van der Flier, Wiesje M.
author_sort Mank, Arenda
collection PubMed
description BACKGROUND: Quality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time. We aimed to compare the trajectories of QoL between amyloid-positive and amyloid-negative SCD or MCI patients and to evaluate QoL trajectories along the Alzheimer’s disease (AD) continuum of cognitively normal to dementia. METHODS: We included longitudinal data of 447 subjective cognitive decline (SCD), 276 mild cognitive impairment (MCI), and 417 AD dementia patients from the Amsterdam Dementia Cohort. We compared QoL trajectories (EQ-5D and visual analog scale (VAS)) between (1) amyloid-positive and amyloid-negative SCD or MCI patients and (2) amyloid-positive SCD, MCI, and dementia patients with linear mixed-effect models. The models were adjusted for age, sex, Charlson Comorbidity Index (CCI), education, and EQ-5D scale (3 or 5 level). RESULTS: In SCD, amyloid-positive participants had a higher VAS at baseline but showed a steeper decline over time in EQ-5D and VAS than amyloid-negative participants. Also, in MCI, amyloid-positive patients had higher QoL at baseline but subsequently showed a steeper decline in QoL over time compared to amyloid-negative patients. When we compared amyloid-positive patients along the Alzheimer continuum, we found no difference between SCD, MCI, or dementia in baseline QoL, but QoL decreased at a faster rate in the dementia stage compared with the of SCD and MCI stages. CONCLUSIONS: QoL decreased at a faster rate over time in amyloid-positive SCD or MCI patients than amyloid-negative patients. QoL decreases over time along the entire AD continuum of SCD, MCI and dementia, with the strongest decrease in dementia patients. Knowledge of QoL trajectories is essential for the future evaluation of treatments in AD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01075-8.
format Online
Article
Text
id pubmed-9476356
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94763562022-09-16 A longitudinal study on quality of life along the spectrum of Alzheimer’s disease Mank, Arenda Rijnhart, Judith J. M. van Maurik, Ingrid S. Jönsson, Linus Handels, Ron Bakker, Els D. Teunissen, Charlotte E. van Berckel, Bart N. M. van Harten, Argonde C. Berkhof, Johannes van der Flier, Wiesje M. Alzheimers Res Ther Research BACKGROUND: Quality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time. We aimed to compare the trajectories of QoL between amyloid-positive and amyloid-negative SCD or MCI patients and to evaluate QoL trajectories along the Alzheimer’s disease (AD) continuum of cognitively normal to dementia. METHODS: We included longitudinal data of 447 subjective cognitive decline (SCD), 276 mild cognitive impairment (MCI), and 417 AD dementia patients from the Amsterdam Dementia Cohort. We compared QoL trajectories (EQ-5D and visual analog scale (VAS)) between (1) amyloid-positive and amyloid-negative SCD or MCI patients and (2) amyloid-positive SCD, MCI, and dementia patients with linear mixed-effect models. The models were adjusted for age, sex, Charlson Comorbidity Index (CCI), education, and EQ-5D scale (3 or 5 level). RESULTS: In SCD, amyloid-positive participants had a higher VAS at baseline but showed a steeper decline over time in EQ-5D and VAS than amyloid-negative participants. Also, in MCI, amyloid-positive patients had higher QoL at baseline but subsequently showed a steeper decline in QoL over time compared to amyloid-negative patients. When we compared amyloid-positive patients along the Alzheimer continuum, we found no difference between SCD, MCI, or dementia in baseline QoL, but QoL decreased at a faster rate in the dementia stage compared with the of SCD and MCI stages. CONCLUSIONS: QoL decreased at a faster rate over time in amyloid-positive SCD or MCI patients than amyloid-negative patients. QoL decreases over time along the entire AD continuum of SCD, MCI and dementia, with the strongest decrease in dementia patients. Knowledge of QoL trajectories is essential for the future evaluation of treatments in AD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01075-8. BioMed Central 2022-09-15 /pmc/articles/PMC9476356/ /pubmed/36109800 http://dx.doi.org/10.1186/s13195-022-01075-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mank, Arenda
Rijnhart, Judith J. M.
van Maurik, Ingrid S.
Jönsson, Linus
Handels, Ron
Bakker, Els D.
Teunissen, Charlotte E.
van Berckel, Bart N. M.
van Harten, Argonde C.
Berkhof, Johannes
van der Flier, Wiesje M.
A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
title A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
title_full A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
title_fullStr A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
title_full_unstemmed A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
title_short A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
title_sort longitudinal study on quality of life along the spectrum of alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476356/
https://www.ncbi.nlm.nih.gov/pubmed/36109800
http://dx.doi.org/10.1186/s13195-022-01075-8
work_keys_str_mv AT mankarenda alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT rijnhartjudithjm alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT vanmaurikingrids alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT jonssonlinus alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT handelsron alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT bakkerelsd alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT teunissencharlottee alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT vanberckelbartnm alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT vanhartenargondec alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT berkhofjohannes alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT vanderflierwiesjem alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT mankarenda longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT rijnhartjudithjm longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT vanmaurikingrids longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT jonssonlinus longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT handelsron longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT bakkerelsd longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT teunissencharlottee longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT vanberckelbartnm longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT vanhartenargondec longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT berkhofjohannes longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease
AT vanderflierwiesjem longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease